Alzheimer's genetic risk intensifies neurocognitive slowing associated with diabetes in nondemented older adults

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 4, 2015, Pages 395-402

  McFall, G Peggy ^a   Wiebe, Sandra A ^a   Vergote, David ^a,b   Anstey, Kaarin J ^c   Dixon, Roger A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease genetic risk score; APOE; Neurocognitive speed; Type 2 diabetes; Victoria longitudinal study

Indexed keywords

EID: 84946041157     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.08.002     Document Type: Article

References (49)

1. Anstey K.J., Cherbuin N., Herath P.M. Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. Prev Sci 2013, 14:411-421.
2. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61:661-666.
3. Profenno L.A., Porsteinsson A.P., Faraone S.V. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010, 67:505-512.
4. Awad N., Gagnon M., Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004, 26:1044-1080.
5. Biessels G.J., Strachan M.W., Visseren F.L., Kappelle L.J., Whitmer R.A. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions. Lancet Diabetes Endocrinol 2014, 2:246-255.
6. McCrimmon R.J., Ryan C.M., Frier B.M. Diabetes and cognitive dysfunction. Lancet 2012, 379:2291-2299.
7. McFall G.P., Geall B.P., Fischer A.L., Dolcos S., Dixon R.A. Testing covariates of type 2 diabetes-cognition associations in older adults: Moderating or mediating effects?. Neuropsychology 2010, 24:547-562.
8. McFall G.P., Wiebe S.A., Vergote D., Westaway D., Jhamandas J., Dixon R.A. IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults. Neurobiol Aging 2013, 34:2208-2216.
9. Yeung S.E., Fischer A.L., Dixon R.A. Exploring effects of type 2 diabetes on cognitive functioning in older adults. Neuropsychology 2009, 23:1-9.
10. Jayaraman A., Pike C.J. Alzheimer's disease and type 2 diabetes: Multiple mechanisms contribute to interactions. Curr Diab Rep 2014, 14:476.
11. Lindenberger U., Nagel I.E., Chicherio C., Li S.C., Heekeren H.R., Bäckman L. Age-related decline in brain resources modulates genetic effects on cognitive functioning. Front Neurosci 2008, 2:234.
12. Shaik M.M., Gan S.H., Kamal M.A. Epigenomic approach in understanding Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014, 13:283-289.
13. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
14. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
15. Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013, 45:1452-1458.
16. Brainerd C.J., Reyna V.F., Petersen R.C., Smith G.E., Taub E.S. Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study. Neuropsychology 2011, 25:679-689.
17. Dixon R.A., DeCarlo C.A., MacDonald S.W., Vergote D., Jhamandas J., Westaway D. APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairment. Front Aging Neurosci 2014, 6:236.
18. Laukka E.J., Lovden M., Herlitz A., Karlsson S., Ferencz B., Pantzar A., et al. Genetic effects on old-age cognitive functioning: a population-based study. Psychol Aging 2013, 28:262-274.
19. Small B.J., Rosnick C.B., Fratiglioni L., Bäckman L. Apolipoprotein E and cognitive performance: A meta-analysis. Psychol Aging 2004, 19:592.
20. Wisdom N.M., Callahan J.L., Hawkins K.A. The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. Neurobiol Aging 2011, 32:63-74.
21. Ready R.E., Baran B., Chaudhry M., Schatz K., Gordon J., Spencer R.M. Apolipoprotein E-e4, processing speed, and white matter volume in a genetically enriched sample of midlife adults. Am J Alzheimers Dis Other Demen 2011, 26:463-468.
22. Thambisetty M., An Y., Nalls M., Sojkova J., Swaminathan S., Zhou Y., et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 2013, 73:422-428.
23. Chibnik L.B., Shulman J.M., Leurgans S.E., Schneider J.A., Wilson R.S., Tran D., et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 2011, 69:560-569.
24. Gui H., Jiang C.Q., Cherny S.S., Sham P.C., Xu L., Liu B., et al. Influence of Alzheimer's disease genes on cognitive decline: The Guangzhou Biobank Cohort Study. Neurobiol Aging 2014, 35. 2422.e3-2422.e8.
25. Sweet R.A., Seltman H., Emanuel J.E., Lopez O.L., Becker J.T., Bis J.C., et al. Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. Am J Psychiatry 2012, 169:954-962.
26. Barral S., Bird T., Goate A., Farlow M.R., Diaz-Arrastia R., Bennett D.A., et al. Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory. Neurology 2012, 78:1464-1471.
27. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: Back to the future. Neuron 2010, 68:270-281.
28. Adams H.H.H., de Bruijn R.F.A.G., Hofman A., Uitterlinden A.G., van Duijn C.M., Vernooij M.W., et al. Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimers Dement 2015, http://dx.doi.org/10.1016/j.jalz.2014.12.008.
29. Josefsson M., Luna X., Pudas S., Nilsson L.G., Nyberg L. Genetic and lifestyle predictors of 15-year longitudinal change in episodic memory. J Am Geriatr Soc 2012, 60:2308-2312.
30. RodriguezRodriguez E., SanchezJuan P., VazquezHiguera J.L., Mateo I., Pozueta A., Berciano J., et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm 2013, 120:807-812.
31. Carrasquillo M.M., Crook J.E., Pedraza O., Thomas C.S., Pankratz V.S., Allen M., et al. Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. Neurobiol Aging 2015, 36:60-67.
32. Hertzog C., Dixon R.A., Hultsch D.F., MacDonald S.W. Latent change models of adult cognition: Are changes in processing speed and working memory associated with changes in episodic memory?. Psychol Aging 2003, 18:755-769.
33. Salthouse T.A. The processing-speed theory of adult age differences in cognition. Psychol Rev 1996, 103:403-428.
34. Christensen H., Dear K.B., Anstey K.J., Parslow R.A., Sachdev P., Jorm A.F. Within-occasion intraindividual variability and preclinical diagnostic status: Is intraindividual variability an indicator of mild cognitive impairment?. Neuropsychology 2005, 19:309-317.
35. Dixon R.A., Garrett D.D., Lentz T.L., MacDonald S.W.S., Strauss E., Hultsch D.F. Neurocognitive markers of cognitive impairment: Exploring the roles of speed and inconsistency. Neuropsychology 2007, 21:381-399.
36. Bäckman L., Jones S., Berger A., Laukka E.J., Small B.J. Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis. Neuropsychology 2005, 19:520-531.
37. Dixon R.A., de Frias C.M. The Victoria longitudinal study: From characterizing cognitive aging to illustrating changes in memory compensation. Aging, Neuropsychology, and Cognition 2004, 11:346-376.
38. Dixon R.A., Small B.J., MacDonald S.W.S., McArdle J.J. Yes, memory declines with aging-but when, how, and why?. Memory and aging: Current issues and future directions 2012, 325-347. Psychology Press, New York, NY. M. Naveh-Benjamin, N. Ohta (Eds.).
39. Small B.J., Dixon R.A., McArdle J.J. Tracking cognition-health changes from 55 to 95 years of age. J Gerontol B Psychol Sci Soc Sci 2011, 66:153-161.
40. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
41. Che R., Motsinger-Reif A.A. Evaluation of genetic risk score models in the presence of interaction and linkage disequilibrium. Front Genet 2013, 4:138.
42. Muthén L.K., Muthén B.O. Mplus User's Guide 1998, Muthén & Muthén, Los Angeles, CA.
43. McFall G.P., Wiebe S.A., Vergote D., Jhamandas J., Westaway D., Dixon R.A. IDE (rs6583817) polymorphism and pulse pressure are independently and interactively associated with level and change in executive function in older adults. Psychol Aging 2014, 29:418-430.
44. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007, 39:17-23.
45. Bangen K.J., Gu Y., Gross A.L., Schneider B.C., Skinner J.C., Benitez A., et al. Relationship between type 2 diabetes mellitus and cognitive change in a multiethnic elderly cohort. J Am Geriatr Soc 2015, 63:1075-1083.
46. Moran C., Phan T.G., Chen J., Blizzard L., Beare R., Venn A., et al. Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition. Diabetes Care 2013, 36:4036-4042.
47. Reijmer Y.D., Leemans A., Brundel M., Kappelle L.J., Biessels G.J. Disruption of the cerebral white matter network is related to slowing of information processing speed in patients with type 2 diabetes. Diabetes 2013, 62:2112-2115. Utrecht Vascular Cognitive Impairment Study Group.
48. Reitz C., Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014, 88:640-651.
49. Sapkota S., Vergote D., Westaway D., Jhamandas J., Dixon R.A. Synergistic associations of catechol-O-methyltransferase and brain-derived neurotrophic factor with executive function in aging are selective and modified by apolipoprotein E. Neurobiol Aging 2015, 36:249-256.